"This book is incredibly complete and easy-to-understand for anybody. I certainly recommend it for patients who want to know more about atrial fibrillation than what they will learn from doctors...."

Pierre Jaïs, M.D. Professor of Cardiology, Haut-Lévêque Hospital, Bordeaux, France

"Dear Steve, I saw a patient this morning with your book [in hand] and highlights throughout. She loves it and finds it very useful to help her in dealing with atrial fibrillation."

Dr. Wilber Su Cavanaugh Heart Center, Phoenix, AZ

"Your book [Beat Your A-Fib] is the quintessential most important guide not only for the individual experiencing atrial fibrillation and his family, but also for primary physicians, and cardiologists."

Jane-Alexandra Krehbiel, nurse, blogger and author "Rational Preparedness: A Primer to Preparedness"


"Steve Ryan's summaries of the Boston A-Fib Symposium are terrific. Steve has the ability to synthesize and communicate accurately in clear and simple terms the essence of complex subjects. This is an exceptional skill and a great service to patients with atrial fibrillation."

Dr. Jeremy Ruskin of Mass. General Hospital and Harvard Medical School

"I love your [A-fib.com] website, Patti and Steve! An excellent resource for anybody seeking credible science on atrial fibrillation plus compelling real-life stories from others living with A-Fib. Congratulations…"

Carolyn Thomas, blogger and heart attack survivor; MyHeartSisters.org

"Steve, your website was so helpful. Thank you! After two ablations I am now A-fib free. You are a great help to a lot of people, keep up the good work."

Terry Traver, former A-Fib patient

"If you want to do some research on AF go to A-Fib.com by Steve Ryan, this site was a big help to me, and helped me be free of AF."

Roy Salmon Patient, A-Fib Free; pacemakerclub.com, Sept. 2013

AF Symposium 2015

Daniel W. Singer, MD 100 pix at 300 res

Daniel W. Singer, MD

The Novel Oral Anticoagulants: Xarelto Best Seller

by Steve S. Ryan, PhD, Updated August 2015

Dr. Daniel Singer of Mass General updated our info about the NOACs (Novel Oral Anticoagulants). Rivoraxaban (Xarelto) is now the most commonly prescribed NOAC. (This is somewhat surprising since dabigatran [Pradaxa] was the first NOAC approved by the FDA and for many months was the only alternative to warfarin. But Pradaxa has lost market share, possibly because of the bad publicity about deaths in the ER from not being able to stop bleeding and its law suit settlements.) (See also: Stop Prescribing or Taking Pradaxa: Suspect in 542 Patient Deaths and Warfarin vs. Pradaxa and the Other New Anticoagulants )

NOACs More Prescribed for New Patients Than Warfarin

After a slow start, NOACs are now prescribed by doctors more commonly than warfarin for new A-Fib patients.

How Do We Know Patients are Actually Taking NOACs and Getting Adequate Levels of Anticoagulation?

The obvious problems with NOACs are they are very costly compared to warfarin, and there currently aren’t any reversal agents like there are for warfarin. But Dr. Singer raised another problem. How can we know the patient is taking the NOAC, what anticoagulant level are they reaching? With warfarin we have INR levels and years of experience in monitoring. Dr. Singer thinks that with more time and clinical experience, we may get a better handle on how the NOACs are actually performing.

GI Bleeding Preferable to Brain Bleeds

Some NOACs produce gastrointestinal bleeding and damage. But Dr. Singer pointed out that from his perspective that is acceptable. No one wants to have gastrointestinal bleeding. But compared to intracranial bleeds, GI bleeds are seldom lethal and don’t leave people disabled.

Editor’s Comments:
Dr. Singer didn’t venture to distinguish between the various NOACs because there haven’t been any head-to-head trials. But, in this editor’s opinion, Eliquis tested better and is safer than the others. 
NOTE: Another NOAC Edoxaban (Lixiana) was approved by the FDA in January, 2015. 
Update August 15, 2015:
See also: Edoxaban Compared to Other Blood Thinners.
An experimental drug idarucizumad has show positive results as a reversal agent for Pradaxa (dabigatran). In a new study of 90 patients who had uncontrolled bleeding with Pradaxa, idarucizumad stopped this bleeding within minutes. No serious side effects were reported. FDA approval is pending.
We have previously reported on the reversal agent Andexanet Alfa which is on FDA fast track approval as an antidote to the Factor Xa inhibitors Xarelto and Eliquis. FDA approval is pending.
References for this article







Related Posts

Follow Us
facebook - A-Fib.comtwitter - A-Fib.comlinkedin  - A-Fib.compinterest  - A-Fib.comYouTube: A-Fib Can be Cured!  - A-Fib.com

A-Fib.com is a
501(c)(3) Nonprofit

Your support is needed. Every donation helps, even just $1.00.

We Need You
A-Fib.com Mission Statement
BYA - Alerts ad Green

A-Fib.com top rated by Healthline.com for the third year.
A-Fib.com top rated by Healthline.com for the third year. 2014  2015  2016

Mug - Seek your cure - Beat Your A-Fib 200 pix wide at 300 resEncourage others
with A-Fib
click to order

Home | The A-Fib Coach | Help Support A-Fib.com | A-Fib News Archive | Tell Us What You think | Media Room | GuideStar Seal | HON certification | Disclosures | Terms of Use | Privacy Policy